211 related articles for article (PubMed ID: 37113757)
1. The effect of CFTR modulators on structural lung disease in cystic fibrosis.
Mok LC; Garcia-Uceda A; Cooper MN; Kemner-Van De Corput M; De Bruijne M; Feyaerts N; Rosenow T; De Boeck K; Stick S; Tiddens HAWM
Front Pharmacol; 2023; 14():1147348. PubMed ID: 37113757
[No Abstract] [Full Text] [Related]
2. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
[TBL] [Abstract][Full Text] [Related]
3. PRAGMA-CF. A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis.
Rosenow T; Oudraad MC; Murray CP; Turkovic L; Kuo W; de Bruijne M; Ranganathan SC; Tiddens HA; Stick SM;
Am J Respir Crit Care Med; 2015 May; 191(10):1158-65. PubMed ID: 25756857
[TBL] [Abstract][Full Text] [Related]
4. Objective airway artery dimensions compared to CT scoring methods assessing structural cystic fibrosis lung disease.
Kuo W; Andrinopoulou ER; Perez-Rovira A; Ozturk H; de Bruijne M; Tiddens HA
J Cyst Fibros; 2017 Jan; 16(1):116-123. PubMed ID: 27343002
[TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
6. CFTR Modulators: Current Status and Evolving Knowledge.
Regard L; Martin C; Da Silva J; Burgel PR
Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
[TBL] [Abstract][Full Text] [Related]
7. Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome.
Marsh R; Dos Santos C; Hanson L; Ng C; Major G; Smyth AR; Rivett D; van der Gast C
Microbiol Spectr; 2023 Aug; 11(5):e0117523. PubMed ID: 37607068
[TBL] [Abstract][Full Text] [Related]
8. Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort.
Wijker NE; Vidmar S; Grimwood K; Sly PD; Byrnes CA; Carlin JB; Cooper PJ; Robertson CF; Massie RJ; Kemner van de Corput MPC; Cheney J; Tiddens HAWM; Wainwright CE; ; ; ;
Eur Respir J; 2020 Apr; 55(4):. PubMed ID: 31949117
[TBL] [Abstract][Full Text] [Related]
9. Effects of Lumacaftor-Ivacaftor on Lung Clearance Index, Magnetic Resonance Imaging, and Airway Microbiome in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Boutin S; Wielpütz MO; Joachim C; Frey DL; Wege S; Sommerburg O; Kauczor HU; Stahl M; Dalpke AH; Mall MA
Ann Am Thorac Soc; 2021 Jun; 18(6):971-980. PubMed ID: 33600745
[No Abstract] [Full Text] [Related]
10. The effect of inhaled hypertonic saline on lung structure in children aged 3-6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial.
Tiddens HAWM; Chen Y; Andrinopoulou ER; Davis SD; Rosenfeld M; Ratjen F; Kronmal RA; Hinckley Stukovsky KD; Dasiewicz A; Stick SM;
Lancet Respir Med; 2022 Jul; 10(7):669-678. PubMed ID: 35286860
[TBL] [Abstract][Full Text] [Related]
11. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
[TBL] [Abstract][Full Text] [Related]
13. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
14. Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study.
Tiddens HAWM; Andrinopoulou ER; McIntosh J; Elborn JS; Kerem E; Bouma N; Bosch J; Kemner-van de Corput M
PLoS One; 2020; 15(11):e0240898. PubMed ID: 33141825
[TBL] [Abstract][Full Text] [Related]
15. Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease.
Chandler JD; Margaroli C; Horati H; Kilgore MB; Veltman M; Liu HK; Taurone AJ; Peng L; Guglani L; Uppal K; Go YM; Tiddens HAWM; Scholte BJ; Tirouvanziam R; Jones DP; Janssens HM
Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30190273
[TBL] [Abstract][Full Text] [Related]
16. Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy.
Yuzyuk T; McDonald CM; Zuromski LM; De Biase I; Johnson L; Williams N; Meihls S; Asfour F
J Cyst Fibros; 2023 Nov; 22(6):1027-1035. PubMed ID: 37453889
[TBL] [Abstract][Full Text] [Related]
17. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
[TBL] [Abstract][Full Text] [Related]
18. Lung Transplantation in a New Era in the Field of Cystic Fibrosis.
Huang W; Smith AT; Korotun M; Iacono A; Wang J
Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511977
[TBL] [Abstract][Full Text] [Related]
19. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
O'Carroll M
Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
[TBL] [Abstract][Full Text] [Related]
20. VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.
Simmonds NJ; van der Ent CK; Colombo C; Kinnman N; DeSouza C; Thorat T; Chew ML; Chandarana K; Castellani C
J Cyst Fibros; 2023 Jan; 22(1):124-131. PubMed ID: 35613999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
